WO2000021548A3 - Angiogenically effective unit dose of fgf and method of administering - Google Patents

Angiogenically effective unit dose of fgf and method of administering Download PDF

Info

Publication number
WO2000021548A3
WO2000021548A3 PCT/US1999/022936 US9922936W WO0021548A3 WO 2000021548 A3 WO2000021548 A3 WO 2000021548A3 US 9922936 W US9922936 W US 9922936W WO 0021548 A3 WO0021548 A3 WO 0021548A3
Authority
WO
WIPO (PCT)
Prior art keywords
fgf
angiogenically
mutein
active fragment
present
Prior art date
Application number
PCT/US1999/022936
Other languages
French (fr)
Other versions
WO2000021548A2 (en
Inventor
William M Kavanaugh
Original Assignee
Chiron Corp
Whitehouse Martha Jo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiron Corp, Whitehouse Martha Jo filed Critical Chiron Corp
Priority to EP99951728A priority Critical patent/EP1121141A2/en
Priority to AU64111/99A priority patent/AU6411199A/en
Priority to JP2000575522A priority patent/JP2002527401A/en
Publication of WO2000021548A2 publication Critical patent/WO2000021548A2/en
Publication of WO2000021548A3 publication Critical patent/WO2000021548A3/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18Growth factors; Growth regulators
    • A61K38/1825Fibroblast growth factor [FGF]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Abstract

The present invention has multiple aspects. In particular, in one aspect, the present invention is directed to a unit dose comprising 0.2 νg/kg to 36 νg/kg of a recombinant FGF or an angiogenically active fragment or mutein thereof. In another aspect, the present invention is directed to a pharmaceutical composition comprising an angiogenically effective dose of an FGF or an angiogenically active fragment or mutein thereof, and a pharmaceutically acceptable carrier. Typically, the angiogenically effective dose comprises 0.2 νg/kg to 36 νg/kg of an FGF of any one of SEQ ID NOS: 1-3, 5, 8-10 or 12-14 or and angiogenically active fragment or mutein thereof. In yet another aspect, the present invention is directed to a method for treating a human patient for coronary artery disease, comprising administering into at least one coronary vessel of a human patient in need of treatment for coronary artery disease a safe and angiogenically effective dose of a recombinant FGF of any one of SEQ ID NOS: 1-3, 5, 8-10 or 12-14, or an angiogenically active fragment or mutein thereof.
PCT/US1999/022936 1998-10-13 1999-10-13 Angiogenically effective unit dose of fgf and method of administering WO2000021548A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP99951728A EP1121141A2 (en) 1998-10-13 1999-10-13 Angiogenically effective unit dose of fgf and method of administering
AU64111/99A AU6411199A (en) 1998-10-13 1999-10-13 Angiogenically effective unit dose of fgf and method of administering
JP2000575522A JP2002527401A (en) 1998-10-13 1999-10-13 Angiogenically effective unit dose of FGF and method of administration

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10410398P 1998-10-13 1998-10-13
US60/104,103 1998-10-13

Publications (2)

Publication Number Publication Date
WO2000021548A2 WO2000021548A2 (en) 2000-04-20
WO2000021548A3 true WO2000021548A3 (en) 2000-08-31

Family

ID=22298692

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1999/022936 WO2000021548A2 (en) 1998-10-13 1999-10-13 Angiogenically effective unit dose of fgf and method of administering

Country Status (5)

Country Link
US (4) US6451303B1 (en)
EP (1) EP1121141A2 (en)
JP (3) JP2002527401A (en)
AU (1) AU6411199A (en)
WO (1) WO2000021548A2 (en)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002527401A (en) * 1998-10-13 2002-08-27 カイロン コーポレイション Angiogenically effective unit dose of FGF and method of administration
US20030166550A1 (en) 1999-08-27 2003-09-04 Chiron Corporation Angiogenically effective unit dose of FGF-2 and method of use
US8618052B2 (en) 1998-10-13 2013-12-31 Novartis Vaccines And Diagnostics, Inc. Method of treating coronary artery disease by administering FGF-5
US6992066B2 (en) * 1998-10-16 2006-01-31 Zimmer Orthobiologics, Inc. Povidone-containing carriers for polypeptide growth factors
US7087577B2 (en) * 1998-10-16 2006-08-08 Zimmer Orthobiologies, Inc. Method of promoting natural bypass
AU6634400A (en) * 1999-08-13 2001-03-13 Chiron Corporation Dose of an angiogenic factor and method of administering to improve myocardial blood flow
US20040097996A1 (en) 1999-10-05 2004-05-20 Omnisonics Medical Technologies, Inc. Apparatus and method of removing occlusions using an ultrasonic medical device operating in a transverse mode
US20020115603A1 (en) * 2000-06-22 2002-08-22 Chiron Corporation Methods and compositions for the treatment of peripheral artery disease
AU2001286996A1 (en) * 2000-08-31 2002-03-13 Chiron Corporation Stabilized fgf formulations containing reducing agents
JP2005503120A (en) * 2001-03-27 2005-02-03 マサチューセッツ インスティテュート オブ テクノロジー Methods and products for FGF dimerization
US20030139333A1 (en) * 2002-01-18 2003-07-24 Genetix Pharmaceuticals, Inc. Methods and compositions for promoting angiogenesis
EP1558282A4 (en) * 2002-10-01 2006-04-19 Chiron Corp Anti-cancer and anti-infectious disease compositions and methods for using same
US7195598B2 (en) * 2003-05-23 2007-03-27 Siemens Aktiengesellschaft Method for determining the effectiveness of a medical therapy by analysis of collateral vessels
US7794414B2 (en) 2004-02-09 2010-09-14 Emigrant Bank, N.A. Apparatus and method for an ultrasonic medical device operating in torsional and transverse modes
EP1827472A4 (en) * 2004-12-06 2012-09-05 Univ California Methods for improving the structure and function of arterioles
JP5058822B2 (en) * 2005-01-25 2012-10-24 ファイブ プライム セラピューティクス, インコーポレイテッド Compositions and methods for treating cardiac conditions
EP2155236A1 (en) * 2007-04-10 2010-02-24 The Board of Regents,The University of Texas System Combination therapy for cardiac revascularization and cardiac repair
WO2009142679A2 (en) * 2008-03-26 2009-11-26 Orthologic Corp. Methods for treating acute myocardial infarction
US8623820B2 (en) 2008-05-02 2014-01-07 University Of Western Ontario FGF-9 and its use relating to blood vessels
GB0814302D0 (en) 2008-08-05 2008-10-01 Coretherapix Slu Compounds and methods
TWI527590B (en) * 2011-06-17 2016-04-01 艾瑞斯貿易公司 Freeze-dried formulations of fgf-18
WO2014024173A2 (en) * 2012-08-10 2014-02-13 Florida State University Research Foundation Recombinant human fibroblast growth factor-1 as a novel therapeutic for ischemic diseases and methods thereof
CN108693179A (en) * 2018-05-17 2018-10-23 郑州翱翔医药科技股份有限公司 A kind of rapid identification method of medicinal butyl rubber bung quality
KR102283915B1 (en) * 2019-12-31 2021-08-02 주식회사 알지프로나 The vectors for expressing hFGF1 transformed microalgae for expression those growth factors
KR102273945B1 (en) * 2019-12-31 2021-07-06 주식회사 알지프로나 The vectors for expressing hFGF2 transformed microalgae for expression those growth factors

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4378347A (en) * 1980-06-30 1983-03-29 Franco Wayne P Composition for treating the heart for myocardial infarction

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4296100A (en) 1980-06-30 1981-10-20 Franco Wayne P Method of treating the heart for myocardial infarction
US5464774A (en) 1984-03-05 1995-11-07 The Salk Institute For Biological Studies Bovine basic fibroblast growth factor
US5155214A (en) 1984-03-05 1992-10-13 The Salk Institute For Biological Studies Basic fibroblast growth factor
US4956455A (en) * 1984-03-05 1990-09-11 The Salk Institute For Biological Studies Bovine fibroblast growth factor
US5604293A (en) 1985-09-12 1997-02-18 Scios Inc. Recombinant human basic fibroblast growth factor
US5439818A (en) 1985-09-12 1995-08-08 Scios Nova Inc. DNA encoding human recombinant basic fibroblast growth factor
US5238916A (en) 1987-05-29 1993-08-24 The Trustees Of Columbia University In The City Of New York Oncogene encoded polypeptide having growth factor activity and methods of use thereof
US5155217A (en) 1987-05-29 1992-10-13 The Trustees Of Columbia University In The City Of New York Ongogene encoding polypeptide having growth factor activity
US5750659A (en) 1987-06-16 1998-05-12 New York University Mammalian growth factor
KR890701607A (en) 1987-11-24 1989-12-21 원본미기재 Analogs of fibroblast growth factor
US5108363A (en) * 1988-02-19 1992-04-28 Gensia Pharmaceuticals, Inc. Diagnosis, evaluation and treatment of coronary artery disease by exercise simulation using closed loop drug delivery of an exercise simulating agent beta agonist
AU614137B2 (en) 1988-06-06 1991-08-22 Takeda Chemical Industries Ltd. Stabilized fgf composition and production thereof
US5352589A (en) 1988-09-16 1994-10-04 Farmitalia Carlo Erba S.R.L. Deletion mutant of basic fibroblast growth factor and production thereof
US5137734A (en) 1989-03-22 1992-08-11 Dana Farber Cancer Institute Angiogenic monoglycerides
US5194596A (en) * 1989-07-27 1993-03-16 California Biotechnology Inc. Production of vascular endothelial cell growth factor
DE69018357T2 (en) * 1989-10-06 1995-09-21 Takeda Chemical Industries Ltd Mutein of HST-1 and its production.
US5350836A (en) * 1989-10-12 1994-09-27 Ohio University Growth hormone antagonists
US5126323A (en) 1989-11-16 1992-06-30 Genetics Institute, Inc. Homogeneous purified k-fgf and compositions containing the same
US5612211A (en) 1990-06-08 1997-03-18 New York University Stimulation, production and culturing of hematopoietic progenitor cells by fibroblast growth factors
US5310883A (en) 1990-11-23 1994-05-10 American Cyanamid Company Chimeric fibroblast growth factors
US5206354A (en) 1990-11-23 1993-04-27 American Cyanamid Company Dna sequence encoding active fragment of fibroblast growth factor, hbf-2
US5213570A (en) 1990-12-14 1993-05-25 Mallinckrodt Medical, Inc. System and method for oxygenation of the pericardium
US5137510A (en) 1990-12-14 1992-08-11 Mallinckrodt Medical, Inc. System and method for oxygenation of the heart using subpericardial fluids
US5269326A (en) 1991-10-24 1993-12-14 Georgetown University Method for transvenously accessing the pericardial space via the right auricle for medical procedures
US5244460A (en) 1991-11-27 1993-09-14 The United States Of America As Represented By The Department Of Health And Human Services Method to foster myocardial blood vessel growth and improve blood flow to the heart
US5491220A (en) 1993-09-24 1996-02-13 Yeda Research And Development Co., Ltd. Surface loop structural analogues of fibroblast growth factors
US20030148968A1 (en) * 1995-02-28 2003-08-07 Hammond H. Kirk Techniques and compositions for treating cardiovascular disease by in vivo gene delivery
US5792453A (en) 1995-02-28 1998-08-11 The Regents Of The University Of California Gene transfer-mediated angiogenesis therapy
AU1057097A (en) * 1995-12-22 1997-07-17 Beth Israel Deaconess Medical Center Localized intravascular delivery of growth factors for promotion of angiogenesis
ES2293473T3 (en) * 1998-02-05 2008-03-16 Biosense Webster, Inc. INTRACARDIAC ADMINISTRATION OF FARMACO.
DE69941034D1 (en) 1998-09-03 2009-08-06 Novartis Vaccines & Diagnostic Fgf-2 angiogenic unit effective dose and method of use
US20020072489A1 (en) 1998-10-13 2002-06-13 Whitehouse Martha J. Angiogenically effective unit dose of FGF-2 and method of use
JP2002527401A (en) * 1998-10-13 2002-08-27 カイロン コーポレイション Angiogenically effective unit dose of FGF and method of administration
US20030166550A1 (en) 1999-08-27 2003-09-04 Chiron Corporation Angiogenically effective unit dose of FGF-2 and method of use
US6440934B1 (en) 1998-10-13 2002-08-27 Chiron Corporation Angiogenically effective unit dose of FGF-2 and method of use

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4378347A (en) * 1980-06-30 1983-03-29 Franco Wayne P Composition for treating the heart for myocardial infarction

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
FOLKMAN J.: "Angiogenic therapy for the human heart", CIRCULATION, vol. 97, 1998, pages 628 - 629, XP000891914 *
KIRSCHNER PAMELA B ET AL: "Basic fibroblast growth factor protects against excitotoxicity and chemical hypoxia in both neonatal and adult rats.", JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM 1995, vol. 15, no. 4, 1995, pages 619 - 623, XP000906721, ISSN: 0271-678X *
SELLKE FRANK W ET AL: "Angiogenesis induced by acidic fibroblast growth factor as an alternative method of revascularization for chronic myocardial ischemia.", SURGERY (ST LOUIS) 1996, vol. 120, no. 2, 1996, pages 182 - 188, XP000891931, ISSN: 0039-6060 *

Also Published As

Publication number Publication date
JP2013155193A (en) 2013-08-15
EP1121141A2 (en) 2001-08-08
US20060025343A1 (en) 2006-02-02
AU6411199A (en) 2000-05-01
JP2010174017A (en) 2010-08-12
US20020165160A1 (en) 2002-11-07
US20090170776A1 (en) 2009-07-02
WO2000021548A2 (en) 2000-04-20
JP2002527401A (en) 2002-08-27
US7511019B2 (en) 2009-03-31
US7858584B2 (en) 2010-12-28
US6451303B1 (en) 2002-09-17

Similar Documents

Publication Publication Date Title
WO2000021548A3 (en) Angiogenically effective unit dose of fgf and method of administering
IL135712A (en) Use of recombinant activated protein c in the manufacture of medicaments for treating or preventing acquired hypercoagulable states associated with sepsis
AU2001268680A1 (en) Methods and compositions for the treatment of peripheral artery disease
JP2002527401A5 (en)
UA56989C2 (en) PHYSIOLOGICALLY ACTIVE PEG-CONJUGATE OF a-INTERFERON, A METHOD FOR PREPARING THE SAME, A PHARMACEUTICAL COMPOSITION BASED THEREON AND A METHOD FOR TREATMENT OR PROPHYLAXIS OF IMMUNOMODULAR DISEASES
CA2163112A1 (en) A coagulation factor viii formulation
HK1075409A1 (en) Angiogenically effective unit dose of fgf-2 and method of use fgf-2
WO1999004772A3 (en) Use of levobupivacaine
AU693833B2 (en) Products containing G-CSF and TNF binding protein
BR9813318A (en) Process of treating tumors and macular degeneration in a human or veterinary patient, pharmaceutical composition for treating tumors and macular degeneration in a human or veterinary patient
WO2002058720A3 (en) Angiogenically effective unit dose of fgf-2 and method of use
EP1304108A3 (en) Anti-arrhythmic composition and methods of treatment
GB9023701D0 (en) Medical treatment
JP2002524420A5 (en)
AU1656997A (en) Use of alpha1-adrenoreceptor antagonists in the prevention and treatment of cancer
GR3032224T3 (en) Therapeutic agent for threatened abortion.
WO2004045513A3 (en) Coronary artery disease treatment
WO1998024421A3 (en) Use of dextrin sulphate for the treatment of highly vascular tumours
EP1894570A3 (en) Methods and compositions for the treatment of peripheral artery disease
RU96107031A (en) METHOD FOR TREATMENT OF GENTINGTON CHOREA

Legal Events

Date Code Title Description
ENP Entry into the national phase

Ref country code: AU

Ref document number: 1999 64111

Kind code of ref document: A

Format of ref document f/p: F

AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2000 575522

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 1999951728

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1999951728

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 1999951728

Country of ref document: EP